期刊文献+

干扰SET8在胃癌细胞肿瘤进展和顺铂敏感性中的作用

The role of interfering SET8 expression in tumor progression and sensit ivity of gastriccancer cells to cisplatin
下载PDF
导出
摘要 目的探究SET8对胃癌的进展以及对顺铂敏感性的影响。方法采用免疫组织化学和蛋白质免疫印迹分析胃癌癌组织中SET8表达,采用qRT-PCR检测胃癌细胞中SET8 mRNA水平;胃癌BGC-823细胞转染SET8-shRNA后,采用CCK-8法检测细胞增殖,采用细胞集落形成实验检测细胞集落形成能力,采用transwell法检测细胞的迁移和侵袭能力;最后,采用CCK-8法检测干扰SET8表达对胃癌BGC-823细胞顺铂敏感性的影响。结果胃癌组织及胃癌细胞中SET8表达明显升高;干扰SET8表达可抑制胃癌BGC-823细胞增殖、集落形成、迁移与侵袭,并提高胃癌细胞对顺铂敏感性。结论干扰SET8表达可抑制胃癌细胞进展并提高顺铂敏感性。 Objective To investigate the role of SET8 in the progression and cisplatin sensitivity of gastric cancer.Methods The protein level of SET8 in gastric cancer tissues was analyzed by immunohistochemistry and western blot.The mRNA level of SET8 in gastric cancer cells was analyzed by qRT-PCR.After transfected with SET8-shRNA,the cell proliferation of gastric cancer BGC-823 cells was measured by CCK-8 assay;the abilities of colony forming,migration and invasion were evaluated by colony formation assay and transwell assay,respectively.At last,CCK-8 assay was used to detect the effect of interfering with SET8 expression on cisplatin sensitivity of gastric cancer BGC-823 cells.Results The expression of SET8 was significantly increased in gastric cancer tissues and gastric cancer cells.Interfering with SET8 inhibited proliferation,colony formation,migration and invasion of gastric cancer BGC-823 cells as well as increased the sensitivity of gastric cancer cells to cisplatin.Conclusion Interference with SET8 can inhibit the tumor progression and increase the sensit ivity of gastric cancer cells to cisplatin.
作者 张琪 王文义 Zhang Qi;Wang Wenyi(Department of Oncology,Pingmei Shenma General Medical Group,Pingdingshan 467000,China)
出处 《中国组织化学与细胞化学杂志》 CAS CSCD 2019年第5期422-427,共6页 Chinese Journal of Histochemistry and Cytochemistry
基金 CSCO-齐鲁肿瘤研究基金2018年度资助项目(Y-Q201802-048)。
关键词 SET8 胃癌 迁移 侵袭 顺铂敏感性 SET8 gastric cancer cell migration cell invasion cisplatin sensitivity
  • 相关文献

参考文献5

二级参考文献44

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011,61:69-90.
  • 2Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenih in advanced non-small-cell lung cancer. J Clin Oncol, 2010,28:1835-1842.
  • 3Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 2002,8:2286-2291.
  • 4Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest, 2005,127:978-983.
  • 5Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Enql J Med, 2006,355:983-991.
  • 6Chen S, Zhang J, Wang R, et al. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer, 2010,70:63-70.
  • 7Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Enql J Med, 2007,356: 800-808.
  • 8Bergman AM, Eijk PP, Ruiz van Haperen VW, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonueleotide reductase subunit M1 as the major determinant. Cancer Res, 2005,65:9510-9516.
  • 9Bepler G, Sommers KE, Cantor A, et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol, 2008,3:1112-1118 .
  • 10Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pretreatment biopsies from a three- arm randomized trial in metastatic non-small-cell lung cancer. Oncogene, 2003,22:3548- 3553.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部